Older people with health problems often need some form of intermediate level monitoring, care and treatment services.
Novartis adds Indianapolis site to its manufacturing capacity for radioligand drug Pluvicto
Novartis has the go-ahead from the FDA to manufacture its radiopharmaceutical Pluvicto at a new facility in Indianapolis, marking a step toward addressing burgeoning demand.